The FDA approved ozanimod (Zeposia, Bristol Myers Squibb) for the treatment of adults with moderately to severely active ulcerative colitis (UC).
Ozanimod, a once-daily oral medication, is the first sphingosine 1-phosphate receptor modulator approved in this setting. The mechanism of action by which ozanimod works in UC is unknown but may involve the reduction of lymphocyte migration into the intestines.